Compounds for the treatment of ocular dryness caused by photorefractive surgery
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jun 14, 2007
app pub date -
Dec 9, 2004
filing date -
Dec 9, 2003
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The blocking agents of the electrical activity of the damaged nerve endings of the neuroma can be used for the treatment of dryness of the ocular surface caused by photorefractive surgery, such as excimer laser photorefractive keratectomy or laser-assisted in situ keratomileusis. The administration of said blocking agents, which include antiepileptics, anticonvulsants, anti-arrhythmic drugs, tricyclic antidepressants and local anaesthetics and, in particular, include lidocaine, tocainide, phenyloin, carbamazepine, lamotrigine, mexiletine and pregabalin, effectively reduce the sensations of ocular dryness.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully